Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Robert Litman, Dieter Naber, Lourdes Anta, Javier Martínez, Yuriy Filts & Christoph U Correll. (2023) Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. Neuropsychiatric Disease and Treatment 19, pages 219-232.
Read now
Read now
Timothy Peters-Strickland, Ross A Baker, Pedro Such, Peter Zhang & Jessica J Madera. (2019) The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies. Neuropsychiatric Disease and Treatment 15, pages 1659-1669.
Read now
Read now
Ludger Hargarter, Marjolein Lahaye, Pierre Cherubin, Martin Lambert, Marnina Swarz, Gali Joldygulov, Flavio Vischia, Veronica Chomskaya, Vasilis P. Bozikas, Eva-Maria Tsapakis & Andreas Schreiner. (2018) Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia. The World Journal of Biological Psychiatry 19:sup3, pages S147-S157.
Read now
Read now
Larry Alphs, Cynthia A Bossie, Dong-Jing Fu, Yi-Wen Ma & Jennifer Kern Sliwa. (2014) Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia. Expert Opinion on Pharmacotherapy 15:7, pages 1029-1042.
Read now
Read now
Wagner F. Gattaz, João Alberto de Oliveira Campos, Acioly L.T. Lacerda, Elaine Henna, Sandra Inês Ruschel, Rodrigo A. Bressan, Irismar Reis de Oliveira, Fábio Lopes Rocha, Hamilton M. Grabowski, Ernindo Sacomani$suffix/text()$suffix/text(), Mario R. Louzã, João Quevedo, Hélio Elkis, Dirceu Zorzetto Filho, Cintia de Azevedo-Marques Périco, Fábio Lorea Lawson & José Carlos Appolinário. (2014) Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study. Current Medical Research and Opinion 30:4, pages 695-709.
Read now
Read now
Stefania Ruiu, Maria Antonietta Casu, Gianluca Casu, Sara Piras & Giorgio Marchese. (2012) Effects of controlled-release formulations of atypical antipsychotics on functioning and quality of life of schizophrenic individuals. Expert Opinion on Pharmacotherapy 13:11, pages 1631-1643.
Read now
Read now
Articles from other publishers (15)
Spyridon Siafis, Lasse Brandt, Robert A McCutcheon, Stefan Gutwinski, Johannes Schneider-Thoma, Irene Bighelli, John M Kane, Celso Arango, René S Kahn, W Wolfgang Fleischhacker, Patrick McGorry, William T Carpenter, Peter Falkai, Alkomiet Hasan, Stephen R Marder, Nina Schooler, Rolf R Engel, William G Honer, Robert W Buchanan, Michael Davidson, Mark Weiser, Josef Priller, John M Davis, Oliver D Howes, Christoph U Correll & Stefan Leucht. (2023) Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis. The Lancet Psychiatry.
Crossref
Crossref
Nagesh Pai, Mustafa Acar, Prabhjot Juneja, Mahsa Hosseini Kouhkamari, Sinthuja Siva & Judy Mullan. (2022) Antipsychotic prescribing patterns in Australia: a retrospective analysis. BMC Psychiatry 22:1.
Crossref
Crossref
Giulia M. Giordano, Luigi Giuliani, Andrea Perrottelli, Paola Bucci, Giorgio Di Lorenzo, Alberto Siracusano, Francesco Brando, Pasquale Pezzella, Michele Fabrazzo, Mario Altamura, Antonello Bellomo, Giammarco Cascino, Anna Comparelli, Palmiero Monteleone, Maurizio Pompili, Silvana Galderisi & Mario Maj. (2021) Mismatch Negativity and P3a Impairment through Different Phases of Schizophrenia and Their Association with Real-Life Functioning. Journal of Clinical Medicine 10:24, pages 5838.
Crossref
Crossref
Roland Vauth, Bernardo Carpiniello, Jacek Turczyński, Mikhail Ivanov, Pierre Cherubin, Marjolein Lahaye & Andreas Schreiner. (2020) Relationship between clinical outcomes measures and personal and social performance functioning in a prospective, interventional study in schizophrenia. International Journal of Methods in Psychiatric Research 30:2.
Crossref
Crossref
Els van der Ven, Jennifer Scodes, Cale Basaraba, Luca Pauselli, Franco Mascayano, Ilana Nossel, Iruma Bello, Jennifer Humensky, Ezra Susser, Melanie Wall & Lisa Dixon. (2020) Trajectories of occupational and social functioning in people with recent-onset non-affective psychosis enrolled in specialized early intervention services across New York state. Schizophrenia Research 222, pages 218-226.
Crossref
Crossref
Adam J. Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews & Bernardo Soares. (2019) Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies. Brazilian Journal of Psychiatry 41:6, pages 499-510.
Crossref
Crossref
Christoph U. Correll, Arielle D. Stanford, Amy Claxton, Yangchun Du & Peter J. Weiden. (2019) Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study. Psychiatry Research 274, pages 176-181.
Crossref
Crossref
Dong-Jing Fu, Ibrahim Turkoz, David Walling, Jean-Pierre Lindenmayer, Nina R. Schooler & Larry Alphs. (2018) Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research 192, pages 185-193.
Crossref
Crossref
Jeffrey P. Anderson, Zeynep Icten, Veronica Alas, Carmela Benson & Kruti Joshi. (2017) Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry 17:1.
Crossref
Crossref
Philip M Burgess, Meredith G Harris, Tim Coombs & Jane E Pirkis. (2017) A systematic review of clinician-rated instruments to assess adults’ levels of functioning in specialised public sector mental health services. Australian & New Zealand Journal of Psychiatry 51:4, pages 338-354.
Crossref
Crossref
Ya Mei Bai, Chih Yin Hsiao, Kao Chin Chen, Kai-Lin Huang, I. Hui Lee, Ju-Wei Hsu, Po See Chen & Yen Kuang Yang. (2014) The development of a self-reported scale for measuring functionality in patients with schizophrenia—Self-reported version of the graphic Personal and Social Performance (SRG-PSP) scale. Schizophrenia Research 159:2-3, pages 546-551.
Crossref
Crossref
Armida Mucci, Paola Rucci, Paola Rocca, Paola Bucci, Dino Gibertoni, Eleonora Merlotti, Silvana Galderisi & Mario Maj. (2014) The Specific Level of Functioning Scale: Construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. Schizophrenia Research 159:1, pages 144-150.
Crossref
Crossref
Min-Wei Huang, Tsung-Tsair Yang, Po-Ren Ten, Po-Wen Su, Bo-Jian Wu, Chin-Hong Chan, Tsuo-Hung Lan, I-Chao Liu, Wei-Cheh Chiu, Chun-Ying Li, Kuo-Sheng Cheng & Yu-Chi Yeh. (2012) Effects of paliperidone extended release on the symptoms and functioning of schizophrenia. BMC Clinical Pharmacology 12:1.
Crossref
Crossref
Anny Karinna Pires Mendes Menezes, Gamaliel Macedo, Paulo Mattos, Antonio Reis de Sá Júnior & Mario Rodrigues Louzã. (2012) Personal and Social Performance (PSP) scale for patients with schizophrenia: translation to Portuguese, cross-cultural adaptation and interrater reliability. Jornal Brasileiro de Psiquiatria 61:3, pages 176-180.
Crossref
Crossref
Maria L Figueira & Sofia Brissos. (2011) Measuring psychosocial outcomes in schizophrenia patients. Current Opinion in Psychiatry, pages 1.
Crossref
Crossref